Archives
-
H62 Dual Tubulin–DNMT Inhibition in Leukemia
2026-09-08
The reference study identifies H62, a letermovir derivative, as a preclinical leukemia candidate that simultaneously targets β-tubulin and DNMT1. Its combined effects on microtubule integrity, cell-cycle progression, oxidative stress, differentiation, apoptosis, and epigenetic gene regulation produced strong activity in erythroleukemia models while showing limited cytotoxicity in the reported animal study.
-
Cy7 NHS Ester: Practical Labeling and QC
2026-09-08
Cy7 NHS ester is a water-soluble near-infrared dye for bioimaging and amino-group labeling of proteins, peptides, and related biomolecules, including targets sensitive to organic co-solvents. It is best used in fresh labeling workflows and should be avoided when the target lacks accessible amines or when prepared dye solutions must be stored long term.
-
ESCO2 Drives HCC Proliferation via PI3K/AKT/mTOR
2026-09-07
The reference study links elevated ESCO2 expression with poor hepatocellular carcinoma prognosis and shows that ESCO2 depletion suppresses tumor-cell growth in vitro and in vivo. Its central mechanistic contribution is connecting ESCO2 to PI3K/AKT/mTOR signaling, cell-cycle acceleration, and apoptosis inhibition, while its multi-dataset and functional design provides a useful framework for validating proliferation mechanisms.
-
BH4 Oxidation Links H2O2 to ERK1/2 in DRG Neurons
2026-09-07
The reference study identifies oxidation-derived H2O2, rather than BH4 itself, as a stimulus that activates ERK1/2 signaling in rat dorsal root ganglion neurons through B-Raf and MEK1/2. Its high-content imaging and pharmacological pathway analysis define a potentially selective mechanism linking elevated BH4 metabolism to nociceptor sensitization.
-
Phosphatase Inhibitor Cocktail 1 Guide
2026-09-05
A scenario-based laboratory guide to using Phosphatase Inhibitor Cocktail 1 (100X in DMSO), SKU K1012, for preserving phosphorylation-dependent biology during cell assay follow-up. It connects practical sample-preparation decisions with phosphoproteomic analysis, Western blotting, and reproducible vendor selection.
-
LncDACH1, VSMC Switching, and AVF Neointimal Hyperplasia
2026-09-04
The reference study identifies LncDACH1 as a protective regulator of smooth muscle cell phenotypic switching during arteriovenous fistula neointimal hyperplasia. Its genetic and viral perturbation models connect LncDACH1 loss to HSP90/SRPK1-dependent AKT activation and establish KLF9 as an upstream transcriptional regulator.
-
Phosphatase Inhibitor Cocktail K1015 Guide
2026-09-04
The Phosphatase Inhibitor Cocktail K1015 uses sequential Tube A and Tube B addition to protect protein phosphorylation during sample preparation. Its dual-component design covers serine/threonine, tyrosine, acid, and alkaline phosphatase activities, but it is a research-use sample-protection reagent rather than a therapeutic or diagnostic agent.
-
Hepatic sEH–Nrf2 Axis in Osteoporosis
2026-09-03
A recent study identifies hepatic soluble epoxide hydrolase (sEH) as an upstream regulator of osteoclastogenesis through circulating lipid mediators and suppression of Nrf2 signaling. By combining patient samples, an ovariectomy-induced osteoporosis model, liver-specific sEH knockdown, pharmacological inhibition, and transcriptomics, the work defines a liver–bone axis that connects epoxyeicosatrienoic acids metabolism with redox imbalance and bone loss.
-
Thiazovivin: ROCK Inhibitor Workflow Guide
2026-09-03
Thiazovivin (SKU A5506) is a ROCK inhibitor used to support fibroblast reprogramming and human embryonic stem cell survival after trypsinization. It is intended for controlled stem cell research workflows only, not diagnostic, clinical, or therapeutic use, and the dossier does not define a universal working concentration or exposure time.
-
Eltanexor (KPT-8602) XPO1 Research Workflow
2026-09-02
Build reproducible XPO1 inhibition experiments with Eltanexor (KPT-8602), from DMSO handling and dose-response design to nuclear-retention and organoid assays. The workflow connects hematologic cancer models with emerging colorectal chemoprevention data while separating established product specifications from practical starting recommendations.
-
Gasdermin C Reprograms PDAC Stemness and Immunity
2026-09-02
The 2024 Advanced Science study identifies GSDMC as a nuclear regulator of stemness, epithelial–mesenchymal transition, metastasis, and immune evasion in pancreatic ductal adenocarcinoma, independent of pyroptotic cell death. Its mechanistic findings connect ADAM17-mediated cleavage and nuclear translocation of GSDMC to treatment resistance and suggest a route for improving responses to KRASG12D inhibition and PD-1 blockade.
-
2X HyperFusion High-Fidelity Master Mix for PCR
2026-09-01
2X HyperFusion High-Fidelity Master Mix is a ready-to-use formulation for high accuracy DNA amplification, cloning PCR applications, and difficult amplicons. Its HyperFusion high-fidelity DNA polymerase combines processivity with 3′→5′ proofreading and produces blunt-ended PCR products, while supplier-stated performance claims should be verified under the user’s own reaction conditions.
-
5-Azacytidine Reprograms Dormant Cancer Cells
2026-09-01
The 2023 Cell Reports study shows that 5-Azacytidine combined with all-trans retinoic acid or an RARα agonist can reprogram disseminated cancer cells into a stable dormant state rather than simply eliminating them. The effect depends on restored TGF-β–SMAD4 signaling and suppresses metastatic outgrowth in preclinical head and neck cancer models, providing a mechanistic framework for studying metastasis prevention through epigenetic therapy.
-
GPC3-HSP70 mRNA Vaccine and PD-L1 Blockade
2026-08-31
The reference study develops a targeted mRNA nanovaccine encoding tandem GPC3 cytotoxic T-lymphocyte epitopes fused to HSP70 and shows enhanced antitumor immunity when combined with anti-PD-L1 therapy. Its significance lies in integrating tumor-associated antigen selection, HSP70-mediated immune stimulation, SP94-guided delivery, and checkpoint blockade within one preclinical HCC strategy.
-
Cisplatin, m6A, and DNA-Repair Vulnerability
2026-08-31
Cisplatin is more than a cytotoxic endpoint: it is a mechanistic probe for how RNA regulation, DNA repair, and apoptotic commitment intersect. This thought-leadership framework connects CDDP response biology with findings on the arginine methylation-dependent METTL14–SMN interaction, while distinguishing evidence-supported insight from translational hypotheses.